Background
KwaZulu-Natal (KZN) has the highest burden of HIV infections in South Africa, with continually high rates across the province. Conditions of Alcohol, Substance, and Mood disorders (CASM) substantially increase HIV risk behaviors, especially for high-risk groups. We identified the impact and cost-effectiveness of screening and treatment for alcohol use disorder (AUD) and major depressive disorder (MDD), as a potential strategy to reduce HIV burden in KZN.
Methods
We used an HIV compartmental transmission model to simulate the impact of CASM screening and treatment interventions on HIV diagnosis, treatment, and viral load suppression. We compared prevention as usual (PAU) with a scale-up of screening and treatment for AUD and MDD, using AUDIT-C and PHQ-9 for screening. Treatment included culturally tailored interventions such as motivational interviewing and problem-solving therapy for AUD, and cognitive-behavioral therapy for MDD. High-priority risk groups, identified with public health stakeholders, included adolescent girls and young women ages 15-24 (AGYW), adolescent boys and young men ages 15-24 (ABYM), female sex workers (FSW), men who have sex with men (MSM), and men ages 25-34. Outcomes were infections averted through 2030, quality-adjusted life-years (QALYs) gained, cost/infection averted, and cost/QALY gained. Analyses were based on causal components of HIV-risk associations, using a modified societal perspective with a 3% discount rate and 2022 $US costs.
Results
AUD accounts for 28.3%, MDD accounts for 11.8%, and combined they account for 33.6% of new HIV infections in KZN. Screening and treatment for AUD can reduce new infections by 14.3% at $2000/infection averted and $2900/QALY. Screening and treatment for MDD can reduce new infections by 5.8% at $1900/infection averted and $2600/QALY. Combined, AUD and MDD interventions can reduce new infections by 25.8% at $1600/infection averted and $2250/QALY. The most efficient way to scale up both AUD and MDD interventions is to first target AGYW at $950/infection averted and $1,300/QALY, followed by FSW at $1,000/infection averted and $1,350/QALY, MSM at $1,050/infection averted and $1,450/QALY, men ages 25-34 at $1,650/infection averted and $2,300/QALY, and last, ABYM at $2,250/infection averted and $3,100/QALY.
Conclusions
Scale-up of integrated AUD and MDD screening and treatment on targeted risk groups has the potential to substantially reduce the number of HIV infections in KZN with very favorable cost effectiveness.